All In Biotech

Drug Trial Radar · NCT06391593

PD, PK, and Safety of ALTO-203 in Patients With MDD

Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Mar 25, 2024

Primary completion

Apr 14, 2025

Study completion Apr 21, 2025

Sponsor

Lead sponsor
Alto NeuroscienceIndustry
Sponsor type
Industry
First posted
Apr 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will receive ALTO-203 25 μg and 75 μg, as well as placebo. During the multiple-dose period, participants will receive either ALTO-203 25 μg, 75 μg , or placebo. Safety will be assessed over the single dose and 28-day multiple dose periods.

Conditions

  • Major Depressive Disorder
  • Anhedonia

Interventions

  • ALTO-203 25 μgDrug

    Active, ALTO-203 25 μg

  • ALTO-203 75 μgDrug

    Active, ALTO-203 75 μg

  • PlaceboDrug

    Comparator, Placebo-to-match

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Single Dose Period: To evaluate pharmacodynamic measures in patients with MDD after single doses of 25 μg ALTO-203, 75 μg ALTO-203, and placebo as measured by the alertness and mood components of the Bond-Lader Visual Analog Scale (BL-VAS).Time frame: Single-Dose Treatment Period - Pre-Dose, 1.5 hours, 3 hours, and 5 hours on Day 1 at Treatments 1, 2, and 3
  2. Multi-Dose Period: To assess the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] during the multi-dose treatment period for ALTO-203 25 μg and ALTO-203 75 μg as compared to placebo.Time frame: Multi-Dose Treatment Period Day 1 to Day 35

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site 4058

    Tucson, Arizona

  • Site 4082

    Oceanside, California

  • Site 4023

    Torrance, California

  • Site 4059

    Clermont, Florida

  • Site 4005

    Orlando, Florida

  • Site 4031

    Atlanta, Georgia

  • Site 4054

    Pikesville, Maryland

  • Site 4036

    Las Vegas, Nevada

  • Site 4022

    Marlton, New Jersey

  • Site 4134

    Princeton, New Jersey

  • Site 4075

    Westlake, Ohio

  • Site 4040

    Austin, Texas

  • Site 4072

    Houston, Texas

  • Site 4007

    Clinton, Utah

  • Site 4033

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.